Conjugation with Eight-Arm PEG Markedly Improves the In Vitro Activity and Prolongs the Blood Circulation of Staphylokinase
Authors:
- 24 January 2018
- journal article
- research article
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 29 (2) , 451-458
Abstract
Staphylokinase (SAK) is a profibrinolytic protein and can be used for therapy of acute myocardial infarction and coronary thrombosis. However, SAK suffers from a short serum half-life time (~6 min) that limits its clinical application. PEGylation prolongs the half-life time of SAK, whereas significantly decreases the bioactivity of SAK for the steric shielding effect of PEG. To improve the bioactivity and prolong the half-life time of SAK, 8-arm PEG maleimide (8-arm PEG) was used for conjugation of multiple SAK molecules in one entity. C terminus of SAK was engineered with cysteine residue, followed by reaction with the maleimide moieties of 8-arm PEG to obtain the conjugate (SAKp-PEG). Conjugation with 8-arm PEG retained the secondary structure of SAK, slightly perturbed the tertiary structure of SAK and essentially maintained its in vitro bioactivity by the multivalence of SAK. Conjugation with 8-arm PEG increased the hydrodynamic volume and thus significantly prolonged the half-life time of SAK. SAKp-PEG elicited a 1.4-fold increase in the SAK-specific IgG titers as compared with SAK, and rendered no apparent toxicity to the cardiac, liver and renal functions of mice. Thus, multiple conjugation of a protein with 8-arm PEG was an effective strategy to develop a long-acting protein drug with improved bioactivity and prolonged blood circulation.Keywords
Funding Information
- National Natural Science Foundation of China (81703445, 81700181)
This publication has 26 references indexed in Scilit:
- The Impact of PEGylation on Biological TherapiesBioDrugs, 2008
- Polymer–drug conjugation, recent achievements and general strategiesProgress in Polymer Science, 2007
- Staphylococcus aureus: StaphylokinaseThe International Journal of Biochemistry & Cell Biology, 2006
- PEGylation, successful approach to drug deliveryDrug Discovery Today, 2005
- Pharmacokinetic and biodistribution properties of poly(ethylene glycol)–protein conjugatesAdvanced Drug Delivery Reviews, 2003
- Effect of pegylation on pharmaceuticalsNature Reviews Drug Discovery, 2003
- Peptide and protein PEGylationBiomaterials, 2001
- Polyethylene Glycol–Derivatized Cysteine-Substitution Variants of Recombinant Staphylokinase for Single-Bolus Treatment of Acute Myocardial InfarctionCirculation, 2000
- Role of the N‐terminal region of staphylokinase (SAK): evidence for the participation of the N‐terminal region of SAK in the enzyme–substrate complex formationFEBS Letters, 2000
- Staphylokinase, a fibrin-specific plasminogen activator with therapeutic potential?Blood, 1994